Patient Enrichment Case Study for Tepotinib: Precision medicine program in lung cancer Published 2021-03-12 Download video MP4 360p Recommendations 1:28:26 Cancer Metabolism: From molecules to medicine 05:53 Targeted Therapy in Non-Small Cell Lung Cancer 01:24 Cancer Immunotherapy Side Effects Must Be Addressed Quickly 22:07 Diagnosed with Stage 4 Metastatic Melanoma 18:45 NeuRA Talks - Freedom from schizophrenia by Professor Cyndi Shannon Weickert 1:09:03 The Psychodynamic Diagnostic Process: Nancy McWilliams 30:18 TEDS – The Journey So Far 23:30 Addiction Neuroscience 101 1:20:51 NCCN Patient Webinar: Small Cell Lung Cancer 38:42 Parkinson's Progression Palliative and End of life issues 58:18 KURS EKG - Część 1 05:13 Highlights & Glimpse of the PCT and PMD Summits at the Revere Hotel Boston Common May 1st-2nd, 2023 1:32:16 An Answer to Cancer? Using the immune system to fight cancer -- Longwood Seminar 55:57 Program Spotlight: Computer Science, Mathematics & Statistics 01:18 Amivantamab for NSCLC with MET Exon 14 skipping mutations 57:51 My Advice to Early Career Group Therapists: Irvin Yalom, MD, DLFAGPA 59:00 Aswath Damodaran: Valuations In Challenging Markets | Lunches with Legends #34 39:23 Advances in Lipoprotein (a) | Cardiology Grand Rounds 53:40 The Basics of Data Product Management by Eric Weber, Head of Data Products at Yelp 39:04 Amyotrophic Lateral Sclerosis (ALS) with Brooke Eby @limpbroozkit Similar videos 20:18 Lung cancer and precision medicine 11:53 INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC 02:48 VISION trial: subset efficacy analyses of tepotinib for NSCLC 01:04 Tepotinib: advanced non-small cell lung cancer 03:05 Tepotinib in METex14 skipping alteration NSCLC 06:55 Dr. Aditya Kanteti-Tepotinib in patients (pts) with advanced (NSCLC) with MET amplification (METamp) 49:28 MET Signaling in NSCLC: Challenges and opportunities for biomarker development and drug discovery 36:48 Personalized therapy for NSCLC: Biomarker testing, treatment & management in MET alterations 01:54 Dr. Le on the Rationale for Tepotinib in METex14-Mutant NSCLC 00:58 VISION Trial Produces Positive Data in NSCLC With MET Exon 14 Mutations 00:56 Oncologist’s opinion on the drugs for review capmatinib, tepotinib, crizotinib, and cabozantinib. 57:58 Recent Advances in Lung Cancer 03:35 The Availability of MET Inhibitors for NSCLC 02:06 Tepmetko (Tepotinib)- metastatic non-small cell lung cancer (NSCLC) 01:50 Future lung cancer drug approvals in the UK 23:32 Part 9 - Panel Discussion Metastatic Lung Cancer - Role of Targeted Agents & Immunotherapy- Dr Ullas 41:04 Case Study: Non-Small Cell Lung Cancer (NSCLC) Treatment 02:18 Highlights in lung cancer at ESMO 2022 06:59 Targeted Therapy for Treatment-Naïve RET Fusion-Positive Lung Cancers More results